SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Britain Courts Anthropic Amid US Defense Department Dispute 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
EAST RUTHERFORD, N.J., Sept. 18, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference on September 25, 2017 at 9:10 a.m. EDT in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
IR Associate
Tel: +201 804 3037
Email: [email protected]
